BioMarin's Cerliponase Alfa Data Support Mid-Year Submissions

BioMarin Pharmaceutical Inc.'s cerliponase alfa (BMN 190) significantly slowed the rate of neurodegenerative decline for young patients with CLN2, a form of Batten disease, compared with historical controls in a Phase I/II clinical trial, supporting plans to seek US and EU regulatory approvals within the next few months.